Itochu invests in United Immunity via private placement

Itochu invested in United Immunity via a private placement, taking a minority equity stake. Deal supports United Immunity’s Myeloid Targeting Platform nanoparticle technology, including an in vivo CAR-macrophage cancer therapy program. United Immunity cited JPY 2.2 billion raised from the private-sector capital increase, backed by an AMED grant of up to JPY 2.8 billion. Funding to accelerate global clinical development, scale-up, commercialization of new cancer immunotherapies. Itochu to provide materials supply support, leverage its network to help partnerships across pharmaceutical, healthcare, chemical industries. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Itochu Corporation published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein. (C)